All In Biotech

Drug Trial Radar · NCT05669001

A Study of TCD601 in de Novo Renal Transplant Recipients

A 12-Month, Randomized, Open-Label, Phase IIA Study Evaluating the Safety and Efficacy of Siplizumab in Combination With Belatacept and MPA Compared to Standard of Care Immunosuppression in de Novo Renal Transplant Recipients (ASCEND)

Last checked: Nov 20, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

76

Actual

Start

Dec 28, 2023

Primary completion

Apr 10, 2026

Study completion Apr 10, 2026

Sponsor

Lead sponsor
ITB-Med LLCIndustry
Sponsor type
Industry
First posted
Dec 30, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of TCD601 in combination with Belatacept when compared to standard of care immunosuppression therapy in de novo renal transplant patients.

Conditions

  • Renal Transplantation

Interventions

  • TCD601Biological

    Investigational Product

  • belataceptBiological

    Study Product

  • ATGDrug

    Comparator

  • TACDrug

    Comparator

  • MPADrug

    Immunosuppression Therapy

  • CorticosteroidsDrug

    Immunosuppression Therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of adverse events (AEs) and serious adverse events (SAEs) in Arm 1 compared to Arm 2Time frame: 12 months

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • University of California Davis Medical Center

    Sacramento, California

  • University of California San Francisco Medical Center

    San Francisco, California

  • Tampa General Hospital

    Tampa, Florida

  • Emory University Hospital

    Atlanta, Georgia

  • Northwestern University

    Chicago, Illinois

  • Loyola University Medical Center

    Maywood, Illinois

  • Ochsner Clinic Foundation

    New Orleans, Louisiana

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Henry Ford Hospital

    Detroit, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Atrium Health Wake Forest Baptist Medical Center

    Winston-Salem, North Carolina

  • University of Cincinnati Medical Center

    Cincinnati, Ohio

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • Houston Methodist Hospital

    Houston, Texas

  • University of Virginia Health

    Charlottesville, Virginia

  • Inova Fairfax Hospital Medical Campus

    Falls Church, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.